cold autoimmune hemolytic anemia due to high-grade non hodgkin's b cell lymphoma with weak response to rituximab and chemotherapy regimens.

نویسندگان

behzad nazel khosroshahi emam reza hospital, hamadan university of medical sciences, hamadan, iran ; blood transfusion research center, high institute for research and education in transfusion medicine, tehran, iran.

mohammad jafari department of pathology, school of medicine, hamadan university of medical sciences, hamadan, iran.

hossein vazini department of nursing, hamedan branch, islamic azad university, hamedan, iran.

alireza ahmadi department of hematology and oncology, school of medicine, hamadan university of medical sciences, hamadan, iran.

چکیده

autoimmune hemolytic anemia (aiha) is characterized by shortening of red blood cell (rbc) survival and the presence of autoantibodies directed against autologous rbcs. approximately 20% of autoimmune hemolytic anemia cases are associated with cold-reactive antibody. about half of patients with aiha have no underlying associated disease; these cases are termed primary or idiopathic. secondary cases are associated with underlying diseases or with certain drugs. we report herein a rare case of cold autoimmiune hemolytic anemia due to high-grade non-hodgkin's lymphoma of b-cell type with weak response to rituximab and chemotherapy regimens. for treatment b cell lymphoma, due to lack of treatment response, we used chemotherapy regimens including r- chop for the first time, and then hyper cvad, r- ice and eshap were administered, respectively. for treatment of autoimmune hemolytic anemia, we have used the corticosteroid, rituximab, plasmapheresis and blood transfusion and splenectomy. in spite of all attempts, the patient died of anemia and aggressive lymphoma nine months after diagnosis. to our knowledge, this is a rare report from cold autoimmune hemolytic anemia in combination with high-grade non-hodgkin's lymphoma of b-cell type that is refractory to conventional therapies.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cold Autoimmune Hemolytic Anemia due to High-grade non Hodgkin's B cell Lymphoma with Weak Response to Rituximab and Chemotherapy Regimens

Autoimmune hemolytic anemia (AIHA) is characterized by shortening of red blood cell (RBC) survival and the presence of autoantibodies directed against autologous RBCs. Approximately 20% of autoimmune hemolytic anemia cases are associated with cold-reactive antibody. About half of patients with AIHA have no underlying associated disease; these cases are termed primary or idiopathic. Secondary ca...

متن کامل

Autoimmune Hemolytic Anemia due to Varicella Infection

Varicella is usually benign exanthematous disease, which primarily affects children. The common complications are bacterial infection of skin eruptions, pneumonia, cerebellar ataxia, hepatitis, thrombocytopenia and arthritis [1]. Autoimmune hemolytic anemia (AIHA) is a rare complication of varicella and only few cases are reported [2-5]. Overall the incidence of AIHA in children is as low as 0....

متن کامل

Chronic Hemolytic Anemia Due to Cold

A male, 47, developed chronic hemolytic anemia in association with hi9h titers of cold agglutinins in 1 966. His symptpm of the cold agglutinin syndrome began in 1 951 with cyanosis of the extremities nd face after exposure to cold. In 1 956, hemoglobinuna was first noted after chilling. In 1 962, the cold agglutinin titer was 1 : 1 6,000, and his red cells were coated with complement globulins...

متن کامل

Development of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

متن کامل

Development of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

متن کامل

Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome.

Standard treatment for autoimmune hemolytic anemia (AIHA) due to warm antibodies includes combinations of glucocorticoids, immunosuppressive drugs (mainly azathioprine) and splenectomy. Patients who are refractory or intolerant to these therapies constitute an important therapeutic challenge. Rituximab, an anti-CD20 chimeric monoclonal antibody, can effectively deplete B-cells and is commonly u...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of hematology-oncology and stem cell research

جلد ۹، شماره ۳، صفحات ۱۵۷-۱۶۰

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023